PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy

Prostate Cancer Clinical Trial

— PROPS  

Official title:

PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02131649
• Other study ID #: GAP02-01.1
• Status: Completed
• Phase: N/A
• Start date: February 2015
• Est. completion date: January 2021

Study information

• Verified date: April 2022
• Source: Lawson Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The PROPS trial is for men being considered for radiotherapy due to the suspicion that their prostate cancer has recurred following the surgical removal of their prostate (prostatectomy). This suspicion is based on rises seen on Prostate Specific Antigen (PSA) blood tests. Only men who demonstrate the absence of disease on standard imaging scans (Computed Tomography (CT) and bone scans) will be invited to participate.

This study will be assessing if the imaging probe 18-F Fluorocholine (18F-FCH) used during Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) scans, can better predict who will benefit from radiotherapy by identifying the source of cancer recurrence. This will be determined by measuring the number of men who have disease identified outside of the prostate bed (the small pocket or depression where the prostate used to be) on their 18F-FCH PET scan. Since F-18-FCH has been shown to be more sensitive in detecting prostate cancer that may have spread into lymph nodes or bone, it may potentially identify areas of prostate cancer spread not seen with standard imaging.

Description:

The study will be a non-randomized, prospective study of men with suspected local recurrence of prostate cancer post-prostatectomy with negative conventional re-staging studies (bone scan and CT of the abdomen and pelvis; MRI of the pelvis as part of re-staging is allowed where it is the institutional standard of care). The clinician will develop an initial treatment plan based on conventional re-staging information.

Patients enrolled onto trial will undergo hybrid PET/MR imaging using 18F-FCH (sites without access to a hybrid PET/MR scanner will conduct a 18F-FCH PET/CT in addition to a full body MRI). A consensus staging report based on local and centralized review of the 18F-FCH PET imaging will be provided to the attending clinician, who will document a second treatment plan based on this additional information. The treatment plan to be implemented (initial or second) will be left to clinician discretion, but will be documented.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 99
• Est. completion date: January 2021
• Est. primary completion date: January 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male, aged 18 years or older.

• Confirmation of prostate cancer on prostatectomy pathology report.

• No lymph node involvement (N0 or Nx) reported on prostatectomy pathology report.

• Documented PSA rise measured on 3 occasions.

• PSA = 0.2 ng/ml at enrolment.

• At least one adverse feature: Current PSA > or equal to 1.0, Initial Gleason Grade > or equal to 8, Positive surgical margin, pT3b (seminal vesicle involvement), or PSA doubling time < 10 months.

• Bone scan and CT scan within 12 weeks of enrolment negative or equivocal for metastatic disease.

• Suitable candidate for radiotherapy and not yet had any salvage treatment post-prostatectomy.

Exclusion Criteria:

• Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components.

• Proven metastatic disease.

• Patients who refuse salvage prostate bed radiotherapy.

• Patients who refuse to join the trial or are unable to consent.

• Patients not being considered for further therapy.

• Patients who cannot lie still for at least 30 minutes or comply with imaging.

• Unequivocal evidence of disease outside the prostate bed on conventional imaging

• Allergy to MRI contrast agent (exclusion for MRI component only) or PET tracer to be used as part of the imaging

• Sickle cell disease or other anemias

• Insufficient renal function (eGFR < 30 mL/min/1.73 m2)

• Residual bladder volume > 150 cc (determined by post-void ultrasound)

• Hip prosthesis, vascular grafting or other conditions affecting imaging or delivery of therapeutic radiation

• Contraindication to MRI, including but not restricted to: pacemaker or other electronic implants, known metal in the orbit, MR incompatible surgical or cerebral aneurysm clips, Shrapnel, tattoos, non-removable body piercings (relative contraindications)

• Hormone Androgen deprivation therapy of any type within 6 months prior to enrollment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• 18F-FCH PET/MRI Scan
Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.

Locations

Country	Name	City	State
Australia	Austin Hospital	Melbourne	Victoria
Australia	Eastern Health	Melbourne	Victoria
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria
Australia	St. Vincent's Hospital	Sydney	New South Wales
Canada	Universite Laval Quebec	Laval	Quebec
Canada	Lawson Health Research Institute, London Health Sciences Centre	London	Ontario
Canada	University of Toronto	Toronto	Ontario
United Kingdom	Velindre Cancer Centre	Cardiff	South Glamorgan
United Kingdom	Royal Marsden Hospital	London
United Kingdom	University College London Hospital	London

Sponsors (1)

Lead Sponsor	Collaborator
Lawson Health Research Institute

Countries where clinical trial is conducted

Australia,  Canada,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of men with negative or equivocal conventional restaging imaging (bone scan + CT scan of abdomen and pelvis) with uptake identified outside of the prostate bed on 18F-FCH PET		Within 2 weeks of 18F-FCH PET scan
Secondary	Biochemical disease free survival at 3 years post-treatment	Whether biochemical (PSA) control rates 3 years post-treatment are improved for participants with 18F-FCH PET imaging that was negative or demonstrated uptake confined to the prostate bed and received salvage pelvic radiotherapy compared to published results for men with adverse features.	3 years post-treatment